Skip to main content
Top
Published in: Gut Pathogens 1/2023

Open Access 01-12-2023 | Campylobacter | Case Report

Vertebral osteomyelitis caused by Campylobacter jejuni in an immunocompetent patient

Authors: Karina Frahm Kirk, Jeppe Boel, Hans Linde Nielsen

Published in: Gut Pathogens | Issue 1/2023

Login to get access

Abstract

Background

Campylobacter jejuni is the leading cause of human bacterial gastroenteritis worldwide. However, systemic infection with C. jejuni is uncommon, and osteomyelitis caused by C. jejuni is extremely rare. Cultivation from spinal bone biopsies has not previously been reported in the literature.

Case presentation

A 79-year-old immunocompetent male was admitted to the emergency department at Aalborg University Hospital in Denmark with lower back pain, fever and diarrhoea. A FecalSwab obtained upon admission was PCR-positive for Campylobacter spp, while an aerobic blood culture bottle was positive for C. jejuni (Time to detection: 70.4 h). A MRI of columna totalis showed osteomyelitis at L1/L2 with an epidural abscess from L1 to L2 with compression of the dura sack. The patient underwent spinal surgery with spondylodesis and decompression of L1/L2. The surgery was uncomplicated and the discus material was also culture positive for C. jejuni. The patient was treated with meropenem for a total duration of four weeks, followed by four weeks of oral treatment with clindamycin in tapered dosage. The patient recovered quickly following surgery and targeted antibiotic treatment with decreasing lumbar pain and biochemical response and was fully recovered at follow-up three months after end of treatment.

Conclusions

While C. jejuni osteomyelitis is rare, it should still be suspected as a possible causative bacterial aetiology in patients with vertebral osteomyelitis, in particular when symptoms of diarrhoea is involved in the clinical presentation. Susceptibility testing is crucial due to emerging resistance, and targeted treatment strategies should rely upon such tests.
Literature
2.
go back to reference Blaser MJEJ. Campylobacter. Washington DC: ASM Press; 2008. Blaser MJEJ. Campylobacter. Washington DC: ASM Press; 2008.
4.
go back to reference Nielsen H, Hansen KK, Gradel KO, Kristensen B, Ejlertsen T, Ostergaard C, et al. Bacteraemia as a result of Campylobacter species: a population-based study of epidemiology and clinical risk factors. Clin Microbiol Infect. 2010;16:57–61.CrossRefPubMed Nielsen H, Hansen KK, Gradel KO, Kristensen B, Ejlertsen T, Ostergaard C, et al. Bacteraemia as a result of Campylobacter species: a population-based study of epidemiology and clinical risk factors. Clin Microbiol Infect. 2010;16:57–61.CrossRefPubMed
5.
go back to reference Tinevez C, Velardo F, Ranc AG, Dubois D, Pailhories H, Codde C, et al. Retrospective multicentric study on Campylobacter Spp. Bacteremia in France: the Campylobacteremia Study. Clin Infect Dis. 2022;75:702–9.CrossRefPubMed Tinevez C, Velardo F, Ranc AG, Dubois D, Pailhories H, Codde C, et al. Retrospective multicentric study on Campylobacter Spp. Bacteremia in France: the Campylobacteremia Study. Clin Infect Dis. 2022;75:702–9.CrossRefPubMed
6.
go back to reference Conan Y, Laurent E, Belin Y, Lacasse M, Amelot A, Mulleman D, et al. Large increase of vertebral osteomyelitis in France: a 2010–2019 cross-sectional study. Epidemiol Infect. 2021;149:e227.CrossRefPubMedPubMedCentral Conan Y, Laurent E, Belin Y, Lacasse M, Amelot A, Mulleman D, et al. Large increase of vertebral osteomyelitis in France: a 2010–2019 cross-sectional study. Epidemiol Infect. 2021;149:e227.CrossRefPubMedPubMedCentral
7.
go back to reference Poulsen SH, Sogaard KK, Fuursted K, Nielsen HL. Evaluating the diagnostic accuracy and clinical utility of 16S and 18S rRNA gene targeted next-generation sequencing based on five years of clinical experience. Infect Dis (Lond). 2023:1–9. Poulsen SH, Sogaard KK, Fuursted K, Nielsen HL. Evaluating the diagnostic accuracy and clinical utility of 16S and 18S rRNA gene targeted next-generation sequencing based on five years of clinical experience. Infect Dis (Lond). 2023:1–9.
9.
go back to reference Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother. 2010;65(Suppl 3):iii11–24.PubMed Gouliouris T, Aliyu SH, Brown NM. Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother. 2010;65(Suppl 3):iii11–24.PubMed
10.
11.
go back to reference Khanna K, Sabharwal S. Spinal Tuberculosis: a comprehensive review for the modern spine surgeon. Spine J. 2019;19:1858–70.CrossRefPubMed Khanna K, Sabharwal S. Spinal Tuberculosis: a comprehensive review for the modern spine surgeon. Spine J. 2019;19:1858–70.CrossRefPubMed
12.
go back to reference Koubaa M, Maaloul I, Marrakchi C, Lahiani D, Hammami B, Mnif Z, et al. Spinal brucellosis in South of Tunisia: review of 32 cases. Spine J. 2014;14:1538–44.CrossRefPubMed Koubaa M, Maaloul I, Marrakchi C, Lahiani D, Hammami B, Mnif Z, et al. Spinal brucellosis in South of Tunisia: review of 32 cases. Spine J. 2014;14:1538–44.CrossRefPubMed
13.
14.
go back to reference Chong BSW, Brereton CJ, Gordon A, Davis JS, Epidemiology. Microbiological diagnosis, and clinical outcomes in pyogenic vertebral osteomyelitis: a 10-year Retrospective Cohort Study. Open Forum Infect Dis. 2018;5:ofy037.CrossRefPubMedPubMedCentral Chong BSW, Brereton CJ, Gordon A, Davis JS, Epidemiology. Microbiological diagnosis, and clinical outcomes in pyogenic vertebral osteomyelitis: a 10-year Retrospective Cohort Study. Open Forum Infect Dis. 2018;5:ofy037.CrossRefPubMedPubMedCentral
15.
go back to reference Liu YH, Yamazaki W, Huang YT, Liao CH, Sheng WH, Hsueh PR. Clinical and microbiological characteristics of patients with bacteremia caused by Campylobacter species with an emphasis on the subspecies of C. fetus. J Microbiol Immunol Infect. 2019;52:122–31.CrossRefPubMed Liu YH, Yamazaki W, Huang YT, Liao CH, Sheng WH, Hsueh PR. Clinical and microbiological characteristics of patients with bacteremia caused by Campylobacter species with an emphasis on the subspecies of C. fetus. J Microbiol Immunol Infect. 2019;52:122–31.CrossRefPubMed
16.
go back to reference Chaillon A, Baty G, Lauvin MA, Besnier JM, Goudeau A, Lanotte P. Campylobacter fetus subspecies fetus spondylodiscitis. J Med Microbiol. 2010;59:1505–8.CrossRefPubMed Chaillon A, Baty G, Lauvin MA, Besnier JM, Goudeau A, Lanotte P. Campylobacter fetus subspecies fetus spondylodiscitis. J Med Microbiol. 2010;59:1505–8.CrossRefPubMed
17.
go back to reference Wong JS, Anderson TP, Chambers ST, On SL, Murdoch DR. Campylobacter fetus-associated epidural abscess and bacteremia. J Clin Microbiol. 2009;47:857–8.CrossRefPubMedPubMedCentral Wong JS, Anderson TP, Chambers ST, On SL, Murdoch DR. Campylobacter fetus-associated epidural abscess and bacteremia. J Clin Microbiol. 2009;47:857–8.CrossRefPubMedPubMedCentral
18.
go back to reference Yamashita K, Aoki Y, Hiroshima K. Pyogenic vertebral osteomyelitis caused by Campylobacter fetus subspecies fetus. A case report. Spine (Phila Pa 1976). 1999;24:582–4.CrossRefPubMed Yamashita K, Aoki Y, Hiroshima K. Pyogenic vertebral osteomyelitis caused by Campylobacter fetus subspecies fetus. A case report. Spine (Phila Pa 1976). 1999;24:582–4.CrossRefPubMed
19.
go back to reference Feodoroff B, Lauhio A, Ellstrom P, Rautelin H. A nationwide study of Campylobacter jejuni and Campylobacter coli bacteremia in Finland over a 10-year period, 1998–2007, with special reference to clinical characteristics and antimicrobial susceptibility. Clin Infect Dis. 2011;53:e99–e106.CrossRefPubMedPubMedCentral Feodoroff B, Lauhio A, Ellstrom P, Rautelin H. A nationwide study of Campylobacter jejuni and Campylobacter coli bacteremia in Finland over a 10-year period, 1998–2007, with special reference to clinical characteristics and antimicrobial susceptibility. Clin Infect Dis. 2011;53:e99–e106.CrossRefPubMedPubMedCentral
20.
go back to reference Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61:e26–46.CrossRefPubMed Berbari EF, Kanj SS, Kowalski TJ, Darouiche RO, Widmer AF, Schmitt SK, et al. 2015 Infectious Diseases Society of America (IDSA) Clinical Practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults. Clin Infect Dis. 2015;61:e26–46.CrossRefPubMed
21.
go back to reference Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2015;385:875–82.CrossRefPubMed Bernard L, Dinh A, Ghout I, Simo D, Zeller V, Issartel B, et al. Antibiotic treatment for 6 weeks versus 12 weeks in patients with pyogenic vertebral osteomyelitis: an open-label, non-inferiority, randomised, controlled trial. Lancet. 2015;385:875–82.CrossRefPubMed
22.
go back to reference Park KH, Cho OH, Lee JH, Park JS, Ryu KN, Park SY, et al. Optimal duration of antibiotic therapy in patients with hematogenous vertebral osteomyelitis at Low Risk and high risk of recurrence. Clin Infect Dis. 2016;62:1262–9.CrossRefPubMed Park KH, Cho OH, Lee JH, Park JS, Ryu KN, Park SY, et al. Optimal duration of antibiotic therapy in patients with hematogenous vertebral osteomyelitis at Low Risk and high risk of recurrence. Clin Infect Dis. 2016;62:1262–9.CrossRefPubMed
23.
go back to reference DANMAP. Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals. food and humans in Denmark; 2021. DANMAP. Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals. food and humans in Denmark; 2021.
24.
go back to reference Tappe D, Schulze MH, Oesterlein A, Abele-Horn M, Baron S, Durchholz D, et al. Molecular detection of Campylobacter jejuni as a cause of culture-negative spondylodiscitis. J Clin Microbiol. 2012;50:1499–500.CrossRefPubMedPubMedCentral Tappe D, Schulze MH, Oesterlein A, Abele-Horn M, Baron S, Durchholz D, et al. Molecular detection of Campylobacter jejuni as a cause of culture-negative spondylodiscitis. J Clin Microbiol. 2012;50:1499–500.CrossRefPubMedPubMedCentral
25.
26.
go back to reference Elharrif Z, Megraud F, Marchand AM. Susceptibility of Campylobacter jejuni and Campylobacter coli to macrolides and related compounds. Antimicrob Agents Chemother. 1985;28:695–7.CrossRefPubMedPubMedCentral Elharrif Z, Megraud F, Marchand AM. Susceptibility of Campylobacter jejuni and Campylobacter coli to macrolides and related compounds. Antimicrob Agents Chemother. 1985;28:695–7.CrossRefPubMedPubMedCentral
27.
go back to reference Michel J, Rogol M, Dickman D. Susceptibility of clinical isolates of Campylobacter jejuni to sixteen antimicrobial agents. Antimicrob Agents Chemother. 1983;23:796–7.CrossRefPubMedPubMedCentral Michel J, Rogol M, Dickman D. Susceptibility of clinical isolates of Campylobacter jejuni to sixteen antimicrobial agents. Antimicrob Agents Chemother. 1983;23:796–7.CrossRefPubMedPubMedCentral
Metadata
Title
Vertebral osteomyelitis caused by Campylobacter jejuni in an immunocompetent patient
Authors
Karina Frahm Kirk
Jeppe Boel
Hans Linde Nielsen
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Gut Pathogens / Issue 1/2023
Electronic ISSN: 1757-4749
DOI
https://doi.org/10.1186/s13099-023-00589-2

Other articles of this Issue 1/2023

Gut Pathogens 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.